FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna

USA - English

• USA - English

NEW YORK, June 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

--
Biogen Idec Inc. Analyst Notes
On June 6, 2014, Biogen Idec Inc. (Biogen Idec) announced that the U.S. Food and Drug Administration (FDA) has approved ELOCTATE™ [Antihemophilic Factor (Recombinant, Fc Fusion Protein]. Biogen Idec stated that ELOCTATE is the first recombinant hemophilia A therapy with prolonged circulation in the body, and is the only treatment for hemophilia A to reduce the frequency of bleeding episodes with prophylactic infusions every three to five days, providing the possibility of extended interval between prophylactic infusions. The Company added that ELOCTATE is used for perioperative (surgical) management on hemophilia A patients both adults and children. George A. Scangos, Ph.D., CEO, Biogen Idec said, "The proven ability of ELOCTATE to provide protection from bleeding episodes with prolonged circulation marks the first significant hemophilia A treatment advance in more than 20 years. As a company deeply committed to improving the lives of people with hemophilia, we are excited to bring this important innovation to those living with hemophilia A." The full analyst notes on Biogen Idec are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/BIIB/report.pdf

--
UnitedHealth Group Inc. Analyst Notes
On June 4, 2014, UnitedHealth Group Inc. (UnitedHealth Group) announced that its Board of Directors authorized payment of a cash dividend of $0.375 per share, payable on June 25, 2014, to all shareholders of record of the Company's common stock as of the close of business on June 16, 2014. According to the Company, this represents a 34% increase over the quarterly dividend of $0.28 per share, which UnitedHealth Group has paid beginning with the Q2 2013. UnitedHealth Group added that its Board has also renewed the Company's Share Repurchase Program which authorizes the purchase of 100 million shares over time, replacing the remainder of the June 2013 authorization. The Company reported that as of May 31, 2014, approximately 63 million shares remain under the prior authorization, and the Company had approximately one billion outstanding common shares. The full analyst notes on UnitedHealth Group are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/UNH/report.pdf

--
GW Pharmaceuticals PLC Analyst Notes
On June 6, 2014, GW Pharmaceuticals PLC (GW Pharmaceuticals) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Epidiolex®, GW Pharmaceuticals' investigational cannabidiol (CBD) product for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. According to the Company, FDA's Fast Track program facilitates the development and review of drugs that are intended for treatment of serious conditions and fill an unmet medical need. Justin Gover, GW Pharmaceuticals' CEO, said, "With GW having already opened an Investigational New Drug (IND) for Epidiolex, we are on track to commence a Phase 2/3 clinical trial in Dravet syndrome in the second half of this year." The full analyst notes on GW Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/GWPH/report.pdf

--
Questcor Pharmaceuticals Inc. Analyst Notes
On June 3, 2014, Questcor Pharmaceuticals Inc. (Questcor) announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now™ events and its support to various Lupus Awareness Month activities. Questcor stated that it has supported a number of lupus awareness, education, and advocacy activities across the country during Lupus Awareness Month which takes place every May. According to the Company, employees of Questor wore purple on May 16, as part of this effort, in order to show their support for lupus patients and to raise awareness of the disease during the LFA's national Put On Purple (POP) Day. The Company added that it is also sponsoring the LFA's roster of national Walk to End Lupus Now events which is a part of the world's largest lupus walk program held throughout the year. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/QCOR/report.pdf

--
Cigna Corporation Analyst Notes
On June 4, 2014, Cigna Corporation (Cigna) announced enhancements to its operating model by reinforcing its local market organizations and regional and global operational capabilities. The Company reported that Matt Manders has assumed extended leadership responsibilities as President of U.S. Commercial Markets and Global Health Care Operations, with immediate effect. In addition to his current responsibilities, Manders will also handle U.S.-based commercial business with employers and individuals, and the operations team that deliver health care services worldwide. Cigna further reported that Jason Sadler's role has expanded and he is now President for International Markets, with immediate effect, where he will be responsible for all Cigna business originating outside of the U.S. for individuals and employers. The full analyst notes on Cigna are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/CI/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review